

## **AI software market value soaring to \$138 billion by 2025**

### **Growing Market Valuation Driving Revenue Projections for BSTO**

RENO, NV, July 23rd, 2024. **Blue Star Opportunities Corp.** (The "Company") (OTC: **BSTO**), announces today that revenue projections for its AI applications are increasingly favorable as AI revenues are expected to outstrip all other software revenues in the information technology sector. According to a recent analysis by the Gartner Group, 2025 is the key year to which Gartner's projections point. "By then, the AI software market will reach a value of \$134.8 billion, with a significant acceleration in its growth." To be more precise, the AI market had grown by 14.4% in 2021, but growth will now jump to 31.1% by 2025, outpacing the growth of the overall software market.

The Company welcomes this confirmation that it can look confidently to positive market performance for its Diomedes AI suite of intelligent apps. The Company is using recent advances in artificial intelligence to offer consumers the ability to monitor their own medication safety and help make up for any gaps by provider organizations as reported in recent studies. Our solutions were already using early forms of AI when the Diomedes legacy applications were tested in major tertiary care hospitals including McGill University affiliates, where it reduced medication errors by 80% as well as reducing inpatient mortality by 50%.

The next milestones for the company's Diomedes AI medication safety apps include completing a user interface designed for individual consumer use, putting in place security measures to safeguard users' personal information and setting up a support desk.

#### **About Blue Star Opportunities Corp**

Blue Star Opportunities Corp (OTC BSTO) deploys a deep bench of knowledge and expertise in developing AI driven systems for solving critical issues impacting people's health. The company's AI driven innovative solutions include apps for individuals to protect themselves against potentially deadly prescription errors, allergies and undesirable reactions. Our latest generation Diomedes applications provide online real time protection against prescription and over-the-counter drug risks. The company continues to derive most of its revenues from its legacy business of renewable high-end cork flooring.

We are also one of the first companies in the world to spearhead the next generation of new, more potent nutraceuticals to promote health through human immune optimization. The recent Covid pandemic has highlighted the need to identify new natural extracts to assist humans optimize their immune systems to better cope with unwelcome invasions by a variety of new pathogens. The company will be promoting and distributing a range of clinically proven Immune RESQ natural extracts.

**FORWARD-LOOKING STATEMENTS:** Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of the Company. These statements are based on suppositions and uncertainties as well as on management best possible evaluation of future events. Such factors may include,

without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for Company products and services, the impact of price pressures exerted by competitors, and general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.

**Media Contact: Michel Dab 438-501-6500**